Overview

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
To find the optimal dose of carboplatin combined with SHR-A1811 in her2-expressed metastatic breast cancer
Phase:
PHASE2
Details
Lead Sponsor:
Anhui Provincial Cancer Hospital